Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Helbig, Grzegorz  [Clear All Filters]
2024
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.
Strzelec A, Gawlik-Rzemieniewska N, Klima A, Panek K, Helbig G. The Impact of Cryopreservation on Hematopoietic Stem Cell Engraftment and Post-transplant Outcome During the COVID-19 Pandemic. In Vivo. 2024;38(3):1271-1277.
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griškevičius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation. Bone Marrow Transplant. 2024.
Włodarczyk M, Wieczorkiewicz-Kabut A, Białas K, Koclęga A, Noster I, Zielińska P, Helbig G. Real-Life Data on Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: Single-Center Analysis. Turk J Haematol. 2024.
Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt HChristian, Bosques L, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol. 2024.
2023
Duda K, Wieczorkiewicz-Kabut A, Koclęga A, Zielińska P, Woźniczka K, Krzemień H, Armatys A, Helbig G. Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience. Ann Hematol. 2023.
Kopińska A, Krawczyk-Kuliś M, Wieczorkiewicz-Kabut A, Koclęga A, Jagoda K, Dziaczkowska-Suszek J, Helbig G. Effect of transplanted cells with CD184, CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma. Exp Hematol. 2023.
Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani MAl, Lioure B, et al. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Gjærde LKlingen, Peczynski C, Polge E, Kröger N, de Latour RPeffault, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, et al. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2023.
2022
Spałek A, Wieczorkiewicz-Kabut A, Koclęga A, Woźniczka K, Węglarz P, Boral K, Kata D, Zielińska P, Helbig G. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience. Int J Hematol. 2022.
2021
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, et al. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Pa. Bone Marrow Transplant. 2021.
2020
Gołos A, Gil L, Puła B, Boguradzki P, Hałaburda K, Sawicki W, Sobczyk-Kruszelnicka M, Helbig G, Dybko J, Jurczyszyn A, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. Adv Med Sci. 2020;65(2):429-436.
2012
Kopińska A, Helbig G, Frankiewicz A, Grygoruk-Wiśniowska I, Kyrcz-Krzemień S. Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation. Contemp Oncol (Pozn). 2012;16(3):215-217.